Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System Abstract #1657

Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.
Aim(s): One of the activities of this society include establishing the registry system for NET patients to understand the current status of NET patients in Japan toward the revision of the guideline.
Materials and methods: The NET registry system has been contracted to TRI ,the 3rd party institute outside of JNETS with the financial support from JNETS. The JNETS members register the patients diagnosed as pancreatic, gastrointestinal, or lung/thoracic NET after 2012 with opt-in consent, starting on January 2015. The data registered in this system are examined by JNETS members to resolve clinical questions for NET disease in Japan.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: M.D., Ph.D. Toshihiko Masui

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1788 Prospective Observational Study 1 on the Prognosis of Patients with Unresectable Advanced Gastrointestinal and Pancreatic Neuroendocrine Tumors (PROP-UP 1 Study) in Japan
Introduction: No previous observational studies on the prognosis of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) [pancreatic neuroendocrine neoplasms (PNENs) and gastrointestinal neuroendocrine neoplasms (GI-NENs)] exist in Japan.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Kazuhiro Toriyama
Keywords: prop-up, japan, gep-nen
#626 Preliminary Results of a Nationwide Survey of Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease in Japan
Introduction: von Hippel–Lindau disease (VHL) is an intractable disease characterized by various tumors including pancreatic neuroendocrine tumors (PNET).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Hisato Igarashi
#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan
Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD,PhD Yasunari Sakamoto
Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, ...
Keywords: Streptozocin, pNETs
#185 Czech Neuroendocrine Registry - First Results
Introduction: The Czech Neuroendocrine Registry was started in October 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Jaroslava Barkmanova
#814 Chromogranin A is a Useful Marker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction: Although Chromogranin A (CgA) is known as a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, the usefulness of CgA in Japanese patients with pNETs is unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Masayuki Hijioka
Authors: Hijioka M, Ito T, Igarashi H, Ueda K, ...